Literature DB >> 35382024

Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud's phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review.

Jan-Gerd Rademacher1, Chris Wincup2,3, Björn Tampe1, Peter Korsten1.   

Abstract

Background: Systemic sclerosis is a rare autoimmune disease characterized by skin and organ fibrosis, and vasculopathy. Raynaud's phenomenon is almost universally present in systemic sclerosis and can be the most debilitating symptom. Raynaud's phenomenon may lead to the development of digital ulcers, potentially complicated by infection, tissue necrosis, and auto-amputation. Recommended treatments have variable efficacy.
Methods: We report the case of a 30-year-old woman with diffuse systemic sclerosis suffering from severe Raynaud's phenomenon and digital ulcers with digital tissue necrosis who was treated with combination therapy of an endothelin receptor antagonist and phosphodiesterase 5 inhibitor. In addition, we reviewed the literature on the topic.
Results: Previous therapy with calcium-channel blockers, intravenous iloprost, and bosentan had all failed to control symptoms. We added sildenafil in combination with bosentan and observed a rapid and sustained treatment effect. Raynaud's phenomenon severity, number of attacks, and attack duration decreased within 2 weeks of initiating treatment. Furthermore, this resulted in the healing of established digital ulcers.
Conclusion: Our case report suggests that combination therapy may be a feasible treatment for the most severely affected and refractory patients. In our literature review, we found one retrospective study and three additional cases with similarly encouraging results.
© The Author(s) 2019.

Entities:  

Keywords:  Raynaud’s phenomenon; digital ulcers; endothelin receptor antagonists; phosphodiesterase inhibitors; systemic sclerosis

Year:  2019        PMID: 35382024      PMCID: PMC8922606          DOI: 10.1177/2397198319876738

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  22 in total

1.  Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.

Authors:  J Gore; R Silver
Journal:  Ann Rheum Dis       Date:  2005-09       Impact factor: 19.103

2.  Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.

Authors:  Gideon A Paul; J Simon R Gibbs; Alan R Boobis; Allifia Abbas; Martin R Wilkins
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

3.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

4.  Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.

Authors:  Roland Fries; Kaveh Shariat; Hubertus von Wilmowsky; Michael Böhm
Journal:  Circulation       Date:  2005-11-08       Impact factor: 29.690

5.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

Review 6.  Digital ulcers in systemic sclerosis.

Authors:  Michael Hughes; Ariane L Herrick
Journal:  Rheumatology (Oxford)       Date:  2016-04-19       Impact factor: 7.580

7.  Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.

Authors:  Florian M P Meier; Klaus W Frommer; Robert Dinser; Ulrich A Walker; Laszlo Czirjak; Christopher P Denton; Yannick Allanore; Oliver Distler; Gabriela Riemekasten; Gabriele Valentini; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2012-05-21       Impact factor: 19.103

8.  Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry.

Authors:  Christopher P Denton; Thomas Krieg; Loic Guillevin; Barbara Schwierin; Daniel Rosenberg; Mariabeth Silkey; Maurice Zultak; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2012-01-12       Impact factor: 19.103

9.  Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.

Authors:  Claudia S Brueckner; Mike O Becker; Thomas Kroencke; Doerte Huscher; Hans Ulrich Scherer; Margitta Worm; Gerd Burmester; Gabriela Riemekasten
Journal:  Ann Rheum Dis       Date:  2009-11-08       Impact factor: 19.103

Review 10.  How does endothelial cell injury start? The role of endothelin in systemic sclerosis.

Authors:  David Abraham; Oliver Distler
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.